Ibida 550 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Rifaximin |
| Company | Healthcare pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of traveler's diarrhea by noninvasive strains of E. coli
- Reduction in risk of overt hepatic encephalopathy
- Bacterial overgrowth of irritable bowel syndrome
Pharmacology
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic. It inhibits bacterial RNA synthesis by its action on the beta-subunit of the DNA-dependent RNA polymerase. It shows broad spectrum activity against many species of Gram-positive and Gram-negative, aerobic and anaerobic bacteria.
Dosage & Administration
- Traveler's Diarrhea: 200 mg 3 times daily for 3 days
- Hepatic Encephalopathy: 550 mg 2 times daily
- Bacterial overgrowth of irritable bowel syndrome:
- 400 mg 3 times daily for 10 days
- 550 mg 3 times daily for 14 days
Interaction
In vitro study has suggested that Ibida induces CYP3A4, but at the recommended dosing regimen is not expected to induce CYP3A4 in patients with normal liver function.
Contraindications
Hypersensitivity to Rifaximin or any rifamycin antimicrobial agents, or any components of the product
Side Effects
- Flatulence
- Headache
- Abdominal pain
- Rectal tenesmus
- Defecation urgency
- Nausea
- Constipation
- Pyrexia
- Vomiting
- Anaphylaxis
- Angioneurotic edema
- Exfoliative dermatitis
Pregnancy & Lactation
Pregnancy category C. Not known whether Rifaximin is excreted in human milk
Precautions & Warnings
- Not effective in patients with diarrhea complicated by fever and/or blood in the stools
- Discontinue if diarrhea symptoms worsen or persist for more than 24-48 hours
- Consider pseudomembranous colitis diagnosis in patients with diarrhea after antibiotic administration
Use in Special Populations
- Renal Impairment: Pharmacokinetics not studied in patients with impaired renal function
- Hepatic Impairment: Systemic exposure markedly elevated in patients with hepatic impairment compared to healthy subjects
Overdose Effects
No specific information available on the treatment of overdose with Ibida. Discontinue Ibida, treat symptomatically, and institute supportive measures as required
Therapeutic Class
4-Quinolone preparations
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children